Vir Biotechnology (VIR) Receivables - Net (2020 - 2022)

Vir Biotechnology has reported Receivables - Net for 3 years, with the latest figure at $7.0 million in Q2 2022.

• Quarterly Receivables - Net changed N/A year-over-year to $7.0 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $7.0 million (changed N/A YoY) and the FY2021 annual result came in at $773.1 million, changed N/A from the prior year.
• Receivables - Net declined to $7.0 million in Q2 2022 per VIR's latest filing, from $1.2 billion in the prior quarter.
• Over five years, Receivables - Net peaked at $1.2 billion in Q1 2022 and troughed at $3.8 million in Q2 2020.
• A 3-year average of $368.8 million and a median of $102.8 million in 2021 frame the typical range for Receivables - Net.
• The widest YoY moves for Receivables - Net: up 987.25% in 2022, down 987.25% in 2022.
• Over 3 years, Receivables - Net stood at $3.8 million in 2020, then jumped by 20244.18% to $773.1 million in 2021, then plunged by 99.09% to $7.0 million in 2022.
• According to Business Quant data, Receivables - Net over the past three periods registered $7.0 million, $1.2 billion, and $773.1 million for Q2 2022, Q1 2022, and Q4 2021 respectively.